Literature DB >> 8312685

Prognostic factors in multiple myeloma: role of beta 2-microglobulin and thymidine kinase.

H Diem1, A Fateh-Moghadam, R Lamerz.   

Abstract

Serum beta 2-microglobulin, serum thymidine kinase, and commonly used prognostic parameters were investigated for their prognostic value in a well-defined group of patients with multiple myeloma (n = 207). Multivariate analysis showed hemoglobin to be the parameter of strongest prognostic value. Only albumin, serum beta 2-microglobulin and serum thymidine kinase added further prognostic information. When tested for efficiency in recognizing patients with poor (average survival time < 1 year) and good (average survival time > 5 years) prognosis, serum beta 2-microglobulin was best (80%), followed by total urinary protein (78%), hemoglobin (76%), and albumin (75%).

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8312685     DOI： 10.1007/bf00185604

Source DB:  PubMed          Journal:  Clin Investig        ISSN： 0941-0198


  16 in total

1.  Expression of thymidine kinase variants is a function of the replicative state of cells.

Authors:  R Adler; B R McAuslan
Journal:  Cell       Date:  1974-06       Impact factor: 41.582

2.  Isolation and properties of a low molecular weight beta-2-globulin occurring in human biological fluids.

Authors:  I Berggård; A G Bearn
Journal:  J Biol Chem       Date:  1968-08-10       Impact factor: 5.157

3.  C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system.

Authors:  R Bataille; M Boccadoro; B Klein; B Durie; A Pileri
Journal:  Blood       Date:  1992-08-01       Impact factor: 22.113

4.  Evaluation of serum deoxythymidine kinase as a marker in multiple myeloma.

Authors:  B Simonsson; C F Källander; G Brenning; A Killander; A Ahre; J S Gronowitz
Journal:  Br J Haematol       Date:  1985-10       Impact factor: 6.998

5.  Prognostic factors in multiple myeloma.

Authors:  R Alexanian; S Balcerzak; J D Bonnet; E A Gehan; A Haut; J S Hewlett; R W Monto
Journal:  Cancer       Date:  1975-10       Impact factor: 6.860

6.  Serum thymidine kinase in monoclonal gammopathies. A prospective study. The Cooperative Group for Study and Treatment of Multiple Myeloma.

Authors:  R Luoni; G Ucci; A Riccardi; P Gobbi; F M Avato; C Vignale; E Ascari
Journal:  Cancer       Date:  1992-03-15       Impact factor: 6.860

7.  Prognostic factors and staging in multiple myeloma: a reappraisal.

Authors:  R Bataille; B G Durie; J Grenier; J Sany
Journal:  J Clin Oncol       Date:  1986-01       Impact factor: 44.544

8.  [Analysis of prognostic factors in plasmacytoma].

Authors:  W Gassmann; T Haferlach; N Schmitz; W Kayser; H H Euler; J Drews; H Löffler
Journal:  Klin Wochenschr       Date:  1984-10-01

9.  Bone marrow histology and serum beta 2 microglobulin in multiple myeloma--a new prognostic strategy.

Authors:  R Bartl; B Frisch; H Diem; M Mündel; A Fateh-Moghadam
Journal:  Eur J Haematol Suppl       Date:  1989

10.  Prognostic features in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults.

Authors: 
Journal:  Br J Cancer       Date:  1980-12       Impact factor: 7.640
View more
  1 in total

1.  High levels of serum β2-microglobulin predict severity of coronary artery disease.

Authors:  Ling You; Ruiqin Xie; Haijuan Hu; Guoqiang Gu; Hongmei Zheng; Jidong Zhang; Xiaohong Yang; Ximiao He; Wei Cui
Journal:  BMC Cardiovasc Disord       Date:  2017-03-01       Impact factor: 2.298
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.